Virbac H1 2026 revenue reaches €768m on 7.4% constant-rate growth as Supercharge platforms deliver double-digit gains

First-half 2026 revenue at Virbac came in at €768m, a gain of 7.4% at constant exchange rate and scope versus the prior-year period. Currency headwinds pulled the actual-rate advance to 4.0%, a 3.4-point gap between the two measures. The Paris-based animal health company credited double-digit growth in its Supercharge platforms as a key driver of the result.

Segment split: companion animal at 10.0%, farm animal at 6.7%

Companion animal posted the sharper gain of the two reporting lines, rising 10.0% in the half. Farm animal grew 6.7%. Both advanced. Virbac described the combination as balanced growth across H1 2026, with the spread between the two segments at 3.3 percentage points. Companion animal's 10.0% rate ran above the 7.4% group CERS figure.

The currency gap in the print

At 7.4% on a constant-rate basis and 4.0% at actual rates, the foreign exchange effect absorbed roughly 3.4 points of the operational advance. Virbac noted the headwinds in the release. No further breakdown of which currencies or regions drove the variance appeared in the source disclosure.

Supercharge platforms pace above the group rate

Double-digit growth in the Supercharge platforms sits above the 7.4% group CERS advance. The release ties that Supercharge performance to the overall half-year result across both the companion animal and farm animal segments. Virbac did not provide a standalone revenue figure for the Supercharge category or specify which products it covers. The double-digit classification puts that cohort's growth above 10%, faster than the aggregate CERS rate.

What to watch

The H1 2026 reporting period closes June 30, 2026. A full-year revenue update or any revision to guidance is the next confirmable data point on the tape.

Related reading

• Globe Life Q2 2026 earnings and conference call set for July 22 after the close; NYSE: GL